Page last updated: 2024-11-05

troglitazone and Testicular Neoplasms

troglitazone has been researched along with Testicular Neoplasms in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hase, T1
Yoshimura, R1
Mitsuhashi, M1
Segawa, Y1
Kawahito, Y1
Wada, S1
Nakatani, T1
Sano, H1

Other Studies

1 other study available for troglitazone and Testicular Neoplasms

ArticleYear
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists.
    Urology, 2002, Volume: 60, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dinoprostone; Gene Expression Regulation,

2002